Violation of drug price control order: Drug cos under NPPA lens for self-exemption from price cap

Pricing watchdog has found that companies such as Lupin and Boehringer Ingelheim launched products bypassing the regulatory framework. The NPPA noted that these drug cos had launched anti-diabetes drugs under para 32 of the DPCO, without submitting the requisite application. This allows the NPPA to exempt certain classes of drugs from price control for a period of five years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/38F5vwA
via IFTTT